Ultragenyx Pharmaceutical (RARE) Competitors $44.75 -2.89 (-6.07%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RARE vs. MRTX, PRGO, BHC, IONS, ACAD, MRNA, SMMT, VTRS, GMAB, and PCVXShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Mirati Therapeutics (MRTX), Perrigo (PRGO), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Moderna (MRNA), Summit Therapeutics (SMMT), Viatris (VTRS), Genmab A/S (GMAB), and Vaxcyte (PCVX). These companies are all part of the "medical" sector. Ultragenyx Pharmaceutical vs. Mirati Therapeutics Perrigo Bausch Health Companies Ionis Pharmaceuticals ACADIA Pharmaceuticals Moderna Summit Therapeutics Viatris Genmab A/S Vaxcyte Mirati Therapeutics (NASDAQ:MRTX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Does the media refer more to MRTX or RARE? In the previous week, Ultragenyx Pharmaceutical had 14 more articles in the media than Mirati Therapeutics. MarketBeat recorded 14 mentions for Ultragenyx Pharmaceutical and 0 mentions for Mirati Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.48 beat Mirati Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Overall Sentiment Mirati Therapeutics Neutral Ultragenyx Pharmaceutical Neutral Is MRTX or RARE more profitable? Ultragenyx Pharmaceutical has a net margin of -106.93% compared to Mirati Therapeutics' net margin of -1,900.65%. Mirati Therapeutics' return on equity of -82.15% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Mirati Therapeutics-1,900.65% -82.15% -67.82% Ultragenyx Pharmaceutical -106.93%-187.12%-37.55% Which has more volatility and risk, MRTX or RARE? Mirati Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Do analysts rate MRTX or RARE? Mirati Therapeutics presently has a consensus price target of $59.00, indicating a potential upside of 0.51%. Ultragenyx Pharmaceutical has a consensus price target of $86.69, indicating a potential upside of 93.73%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mirati Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirati Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Does the MarketBeat Community believe in MRTX or RARE? Ultragenyx Pharmaceutical received 371 more outperform votes than Mirati Therapeutics when rated by MarketBeat users. Likewise, 77.38% of users gave Ultragenyx Pharmaceutical an outperform vote while only 62.95% of users gave Mirati Therapeutics an outperform vote. CompanyUnderperformOutperformMirati TherapeuticsOutperform Votes45762.95% Underperform Votes26937.05% Ultragenyx PharmaceuticalOutperform Votes82877.38% Underperform Votes24222.62% Do insiders & institutionals have more ownership in MRTX or RARE? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 3.3% of Mirati Therapeutics shares are owned by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation and earnings, MRTX or RARE? Ultragenyx Pharmaceutical has higher revenue and earnings than Mirati Therapeutics. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirati Therapeutics$12.44M331.01-$740.87M-$12.22-4.80Ultragenyx Pharmaceutical$434.25M9.52-$606.64M-$6.47-6.92 SummaryUltragenyx Pharmaceutical beats Mirati Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.13B$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.09%4.06%P/E Ratio-6.9210.80101.8517.37Price / Sales9.52266.501,207.8272.25Price / CashN/A53.4940.8436.36Price / Book11.909.306.335.87Net Income-$606.64M$154.14M$119.64M$225.66M7 Day Performance-11.14%-9.49%-5.12%-1.34%1 Month Performance-22.44%-7.23%-3.21%1.00%1 Year Performance14.89%30.70%32.50%25.27% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.6264 of 5 stars$44.75-6.1%$86.69+93.7%+14.9%$4.13B$434.25M-6.921,276Analyst ForecastMRTXMirati Therapeutics0.5808 of 5 stars$58.70flatN/AN/A$4.12B$12.44M-4.80587Analyst ForecastPRGOPerrigo4.9605 of 5 stars$26.70+1.3%N/A-8.2%$3.64B$4.66B-22.829,140BHCBausch Health Companies2.7399 of 5 stars$9.37+0.3%N/A+29.3%$3.45B$8.76B-19.5220,270IONSIonis Pharmaceuticals4.0875 of 5 stars$38.93-0.7%N/A-29.3%$6.15B$788M-15.95800Analyst DowngradeInsider SellingShort Interest ↑News CoverageACADACADIA Pharmaceuticals3.988 of 5 stars$18.37+4.0%N/A-24.0%$3.05B$726.44M23.55510Analyst DowngradeShort Interest ↑MRNAModerna4.5631 of 5 stars$42.38-9.5%N/A-51.9%$16.29B$6.85B-7.285,600Analyst ForecastOptions VolumeGap DownHigh Trading VolumeSMMTSummit Therapeutics2.1933 of 5 stars$21.90+2.3%N/A+884.4%$16.15B$700,000.00-78.21105Gap UpVTRSViatris1.3727 of 5 stars$13.10+1.1%N/A+39.9%$15.64B$15.05B-17.7038,000Insider SellingGMABGenmab A/S4.4263 of 5 stars$23.15+0.3%N/A-35.6%$15.32B$19.84B22.482,204Short Interest ↑PCVXVaxcyte3.3295 of 5 stars$104.02-2.5%N/A+73.3%$12.97BN/A-22.61160News Coverage Related Companies and Tools Related Companies Mirati Therapeutics Alternatives Perrigo Alternatives Bausch Health Companies Alternatives Ionis Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives Moderna Alternatives Summit Therapeutics Alternatives Viatris Alternatives Genmab A/S Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RARE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
